News for Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[552061]**

”“ TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer ”“ ”“ Investigational New Drug (IND) application for TNG456, a next-generation

**media[545498]**

**media[527994]**

Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Explore more details here.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Tango Therapeutics Inc.

November 14, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to investing platform covering biotech and medical technology sto...

On November 7, 2024, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a significant adjustment to its holdings in Tango Therapeutics In

Tango Therapeutics (TNGX) stock plunged 28% Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Read more here.

New Jersey-based DatChat, Inc. (DATS) is up over 97 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Tango Therapeutics is a high-risk, high-reward opportunity in the field of PRMT5-inhibitor drugs targeting MTAP-deleted cancers. Read more on TNGX stock here.

Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is...

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Multibillionaire Joe Lewis to face US sentencing for insider trading

Tango Therapeutics has 2 PRMT5 inhibitors in clinical development. Its shares spiked after positive data from PRMT5 inhibitor. Find out why TNGX stock is a Buy.